lobbying_activities: 1991656

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

id	filing_uuid	filing_type	registrant_name	registrant_id	client_name	filing_year	filing_period	issue_code	specific_issues	government_entities	income_amount	expense_amount	is_no_activity	is_termination	received_date
1991656	fca37d82-3d97-4fd0-9d2c-92c4260e4d01	Q2	WINNING STRATEGIES WASHINGTON	50796	KALEO	2017	second_quarter	PHA	Pharmaceutical drug development including epinephrine for anaphylaxis	HOUSE OF REPRESENTATIVES,Office of Natl Drug Control Policy (NDCP),SENATE	30000		0	0	2017-07-18T13:25:31.510000-04:00